This is a randomized, parallel-arm, open-label, multi-centre, Phase II study to determine the
efficacy and safety of lapatinib in combination with vinorelbine or capecitabine in women
with ErbB2 overexpressing metastatic breast cancer (MBC) who have received no more than one
chemotherapeutic regimen in the metastatic setting.